Silo Pharma, Inc.
SILONasdaq
$4.86
↑ +1.7%Jul 17 close · end-of-day
Price
1Y↓ -46.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$66.6M
Enterprise Value
$60.6M
P/E
—
P/S
924.1
P/B
11.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$72,102.00
Net Income (TTM)
-$4.8M
Free Cash Flow (TTM)
—
Gross Margin
11.9%
Operating Margin
-6631.2%
Net Margin
-6717.4%
ROE
-85.2%
ROIC
—
Debt / Equity
—
Net Cash
$6.0M
Return 1Y
-48.7%
Company profile
Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey. The company focuses on merging traditional therapeutics with psychedelic research for patients with depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland, The Regents of The University of California, and Columbia University.
- CEO
- Eric Weisblum
- Sector
- Manufacturing
- Industry
- Apparel
- Employees
- 2
- Headquarters
- Florida
- Website
- silopharma.com
Earnings
SILO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$18,026.000.0%
Diluted EPS-$0.12↓ -47.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $40,923.00 | — | $72,102.00 | $72,102.00 | $72,102.00 | $72,102.00 |
| Gross profit | -$135,203.00 | $66,260.00 | $66,264.00 | $66,264.00 | $66,264.00 | $27,807.00 |
| Operating income | -$2.2M | -$2.7M | -$3.6M | -$3.9M | -$4.7M | -$4.3M |
| Net income | -$3.0M | $3.9M | -$3.9M | -$3.7M | -$4.4M | -$4.2M |
| Diluted EPS | -$0.05 | $0.04 | — | -$1.20 | -$1.19 | -$0.50 |
| Operating cash flow | -$1.2M | -$2.3M | -$3.5M | -$3.2M | -$3.8M | -$4.7M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | -330.4% | — | 91.9% | 91.9% | 91.9% | 38.6% |
| Operating margin | -5380.2% | — | -5031.3% | -5347.4% | -6526.4% | -5937.0% |
| Net margin | -7422.5% | — | -5420.9% | -5132.6% | -6092.6% | -5863.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18,025.00 | $18,025.00 | $18,026.00 | $18,026.00 | $18,025.00 | $18,025.00 | $18,026.00 | $18,026.00 |
| Gross profit | $16,566.00 | $16,566.00 | $16,566.00 | $16,566.00 | $16,566.00 | -$2,662.00 | -$2,663.00 | -$2,662.00 |
| Operating income | -$1.0M | -$1.0M | -$1.8M | -$1.1M | -$1.2M | -$1.2M | -$786,524.00 | -$1.6M |
| Net income | -$931,779.00 | -$928,814.00 | -$1.7M | -$1.0M | -$1.2M | -$1.1M | -$881,530.00 | -$1.6M |
| Diluted EPS | -$0.31 | -$0.22 | -$0.38 | -$0.23 | -$0.19 | -$0.12 | $0.04 | -$0.12 |
| Operating cash flow | -$731,803.00 | -$1.3M | -$917,432.00 | -$1.6M | -$1.3M | -$955,493.00 | -$780,278.00 | -$822,623.00 |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% | -14.8% | -14.8% | -14.8% |
| Operating margin | -5563.2% | -5603.6% | -10059.6% | -6069.7% | -6926.8% | -6388.2% | -4363.3% | -8846.4% |
| Net margin | -5169.4% | -5152.9% | -9600.7% | -5721.9% | -6681.2% | -6160.5% | -4890.3% | -9137.5% |
Company news
Jul 14, 2026
Jul 10, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-15 | Weisblum Eric· Chief Executive Officer | Buy | 2,500 | $0.42 | $1,050.00 | filing |
| 2025-12-15 | Weisblum Eric· Chief Executive Officer | Buy | 2,500 | $0.41 | $1,025.00 | filing |
| 2025-11-21 | Weisblum Eric· Chief Executive Officer | Buy | 1,000 | $0.37 | $365.00 | filing |
| 2025-11-20 | Weisblum Eric· Chief Executive Officer | Buy | 1,000 | $0.37 | $370.00 | filing |
| 2025-11-19 | Weisblum Eric· Chief Executive Officer | Buy | 4,500 | $0.41 | $1,822.50 | filing |
| 2025-11-18 | Weisblum Eric· Chief Executive Officer | Buy | 7,500 | $0.40 | $3,024.75 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.